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Abstract
Background: New diagnoses of tuberculosis (TB) present important opportunities to detect and treat HIV. Rates of
HIV and TB in Indonesia’s easternmost Papua Province exceed national figures, but data on co-infection rates and
outcomes are lacking. We aimed to measure TB-HIV co-infection rates, examine longitudinal trends, compare
management with World Health Organisation (WHO) recommendations, and document progress and outcome.
Methods: Adults with newly-diagnosed smear-positive pulmonary TB managed at the Timika TB clinic, Papua
Province, were offered voluntary counselling and testing for HIV in accordance with Indonesian National Guidelines,
using a point-of-care antibody test. Positive tests were confirmed with 2 further rapid tests. Study participants were
assessed using clinical, bacteriological, functional and radiological measures and followed up for 6 months.
Results: Of 162 participants, HIV status was determined in 138 (85.2%), of whom 18 (13.0%) were HIV+. Indigenous
Papuans were significantly more likely to be HIV+ than Non-Papuans (Odds Ratio [OR] 4.42, 95% confidence
interval [CI] 1.38-14.23). HIV prevalence among people with TB was significantly higher than during a 2003-4 survey
at the same TB clinic, and substantially higher than the Indonesian national estimate of 3%. Compared with HIV-
study participants, those with TB-HIV co-infection had significantly lower exercise tolerance (median difference in 6-
minute walk test: 25 m, p = 0.04), haemoglobin (mean difference: 1.3 g/dL, p = 0.002), and likelihood of cavitary
disease (OR 0.35, 95% CI 0.12-1.01), and increased occurrence of pleural effusion (OR 3.60, 95% CI 1.70-7.58), higher
rates of hospitalisation or death (OR 11.80, 95% CI 1.82-76.43), but no difference in the likelihood of successful 6-
month treatment outcome. Adherence to WHO guidelines was limited by the absence of integration of TB and HIV
services, specifically, with no on-site ART prescriber available. Only six people had CD4+ T-cell counts recorded, 11
were prescribed co-trimoxazole and 4 received ART before, during or after TB treatment, despite ART being
indicated in 14 according to 2006 WHO guidelines.
Conclusions: TB-HIV co-infection in southern Papua, Indonesia, is a serious emerging problem especially among
the Indigenous population, and has risen rapidly in the last 5 years. Major efforts are required to incorporate new
WHO recommendations on TB-HIV management into national guidelines, and support their implementation in
community settings.
Background
Tuberculosis (TB) and HIV infections are major global
health threats. An estimated 1.4 million new TB cases in
HIV-positive individuals were reported in 2007 [1].
Wide-ranging diagnostic, management and economic
challenges are posed by TB-HIV co-infection. HIV con-
fers the greatest risk for TB, increasing the risk of latent
TB reactivation 20-fold [2,3]. TB is a leading cause of
death among people with HIV [4], and TB patients co-
infected with HIV (HIV+/TB+), especially in the absence
of antiretroviral therapy (ART), have significantly worse
outcomes than those without HIV (HIV-/TB+) [5,6]. TB
treatment regimens appropriate for HIV-negative
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sive phase, and a 6-month rifampicin duration, may be
suboptimal in HIV-positive people [7].
Priorities in addressing TB-HIV co-infection include
instituting the World Health Organisation (WHO)’s ‘3Is’
(Intensified TB case-finding, Isoniazid preventive therapy
and Infection control) [8], ensuring routine ascertain-
ment of HIV status in people with TB [9], close integra-
tion of TB and HIV services [9,10], and universal access
to ART in HIV-positive people [11], including early ART
initiation in TB-HIV co-infection [10,12-14]. Acknowled-
ging the improved outcomes achieved with ART [14],
WHO guidelines have moved beyond 2006 recommenda-
tions guided by CD4 count [10] to now recommend ART
in all people with TB-HIV co-infection [13].
Despite these rapid advances in knowledge, substantial
barriers persist to the achievement of optimised TB-HIV
management goals, especially in lower-income countries.
In tackling the challenge of HIV in people with TB,
multifactorial barriers include failures to implement
HIV testing, failure to prescribe ART or other elements
of HIV care, pre-treatment loss to care and post-ART-
initiation loss to follow up [15].
In Indonesia, HIV infection rates in TB are not routi-
nely reported [16]. A 2006 study utilising unlinked, anon-
ymous testing in people with TB in Yogyakarta found an
HIV seroprevalence rate among TB patients of 1.9% [17].
The overall national estimate is 3% [1]. Papua Province
has long been recognised as having one of the highest
HIV burdens in Indonesia [18]. An ‘Integrated Bio-Beha-
vioral Surveillance’ study in 2006, of 6305 Papua Province
residents aged 15-49 years, reported population HIV ser-
oprevalence as 2.4% [19]. This survey also revealed low
levels of health knowledge: 51.8% overall had heard of
HIV/AIDS (26.3% among those with no or limited educa-
tion). Only 35.4% knew that condom use was protective
[19]. Especially high HIV rates of 26% have been docu-
mented in Papuan female commercial sex workers [18].
Indonesia has had a policy to provide free ART since
2003 [20]. However, national capacity to widely roll out
ART and provide other elements of HIV care is limited
[18,20,21]. HIV voluntary counselling and testing was
taken up by just 4% of TB patients in one 2006 Indone-
sian study [17]. Recent estimates of ART accessibility
indicate that only about 24% of Indonesian people with
advanced HIV infection receive ART; this figure is as
low as 3% in Papua Province [20,21].
Our aims were to describe current TB-HIV epidemiol-
ogy and management in Timika, Papua Province, Indo-
nesia, in order to tailor future interventions. Specifically,
we aimed to investigate the burden of HIV infection
among adults with smear-positive pulmonary TB, to
examine changes over time, to describe current HIV
management and compare with 2006 WHO guidelines
[9], and investigate TB treatment outcomes among TB-
HIV co-infected people.
Methods
Study setting
The study was conducted at a community TB clinic in
Timika, Papua Province, Indonesia. Timika is adjacent
to a major gold and copper mine, and has one of the
highest rates of growth of any urban community in
Indonesia, from an estimated population of 3000 in
1967 to 200 000 in 2009 [22]. Estimated TB incidence is
311/100 000 [23], compared with 228/100 000 for Indo-
nesia overall [1]. The Timika population currently com-
prises approximately half Indigenous Papuans and half
non-Papuan Indonesians.
Participants
Adult outpatients (>15 years) with newly-diagnosed spu-
tum smear positive pulmonary TB who were not pregnant,
agreed to stay in Timika for the study duration, and gave
written informed consent, were eligible for enrolment.
Study participants were recruited June 2008-October 2009
as part of an ongoing trial of adjunctive therapies in TB
(see http://clinicaltrials.gov/show/NCT00677339), and fol-
lowed weekly for 8 weeks, then monthly for 24 weeks.
Information available after 24 weeks regarding HIV care
was also recorded. Ethnicity was documented as Indigen-
ous Papuan or Non-Papuan. Longitudinal trends were
determined by comparing current with previously-
collected data from Timika (an observational study of 112
smear-positive pulmonary TB patients in 2003-4), results
of which are published elsewhere [23-26].
HIV testing
Voluntary counselling and testing (VCT), including
detailed education about HIV/AIDS, was conducted in
accordance with Indonesian national guidelines by a
doctor at the TB clinic, or a trained counsellor at the
adjacent sexual health clinic. Consultations were either
in private, or with a spouse/family member/guardian if
requested by the patient. Study participants could
decline testing, or demonstrate agreement by signing or
applying their thumbprint to the VCT consent form.
The process took 30-60 minutes.
HIV antibody was tested using SD BioLine HIV-1/2
3.0™ antibody test (Standard Diagnostics, Inc). If posi-
tive, two confirmatory rapid tests were performed
(Abbott Determine™ HIV-1/2 [Inverness Medical], and
Oncoprobe™ [PT Oncoprobe Utama]). These tests have
high reported sensitivity and specificity [27,28]. A fluor-
escence-activated cell sorter was used for CD4+ T-cell
assays, when available.
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Baseline and follow-up evaluations included: documen-
tation of clinical history and symptoms, body mass
index (BMI), forced expiratory volume in one second
(FEV1, performed using MicroLoop spirometer, Micro-
Medical), 6-minute walk test (6 MWT: distance walked
in 6 minutes on a straight walking track) measured
according to American Thoracic Society guidelines [29],
St George’s Respiratory Questionnaire (SGRQ: a health-
related quality of life score) modified slightly to reflect
local conditions and translated into Indonesian language
[26,30], chest radiography (standard full-size posteroan-
terior chest x-ray), and haemoglobin measured using
point-of-care iSTAT® tests. Anaemia was defined as hae-
moglobin <13.5 g/dL in males and <11.5 g/dL in
females. Documented chest x-ray findings included per-
centage of abnormal visible lung fields, presence of cavi-
tation, effusion or miliary disease, and an overall score
comprising percentage of lung affected plus a weighting
of 40 if cavitation was present, as described elsewhere
[31]. Sputum microscopy was performed at the onsite
laboratory, with density of acid fast bacilli (AFB) graded
as 1, 2 or 3+ according to standard protocols [32].
Smear negativity was defined as the time point (week
after treatment) at which the first of 3 consecutive nega-
tive results was recorded, or the first negative result if
<2 subsequent results were recorded [33,34]. Pulmonary
function was defined as moderately impaired if FEV1
60-69% predicted, and moderately to severely impaired
if 50-59% predicted [35]. Unfavourable outcomes
were defined as death, life-threatening illness or
hospitalisation.
Reference guidelines
WHO 2006 guidelines were used as the best-practice
reference, recommending ART initiation within 2-8
weeks after TB treatment commencement for CD4 <200
or unknown, after 8 weeks if CD4 200-350, and deferral
of ART if CD4 > 350 [9,10].
Statistical analyses
Statistical calculations were performed using Intercooled
Stata 10.1. Graphs were created in GraphPad Prism 5.
Statistical tests were two-sided, with a p-value of <0.05
indicating statistical significance. Intergroup differences
in means or medians were compared using 2-sample
t-tests or Wilcoxon rank sum tests as appropriate. Dif-
ferences in proportions were calculated using Pearson’s
c
2 test or Fisher’s exact test as appropriate. Multiple lin-
ear regression models were used to determine relation-
ships after controlling for potential confounding factors.
Final model goodness-of-fit was assessed using the Hosmer-
Lemeshow test. Kaplan-Meier survival analysis was used
to examine time-to-event data (time to sputum smear
conversion using weekly sputum smear readings). Patient
subgroup analysis was performed by Cox regression (pro-
portional-hazards) models and hazard ratios and 95% confi-
dence intervals.
Ethics
Approval was granted by the ethics committees of the
National Institute of Health Research and Development
(Jakarta, Indonesia), Menzies School of Health Research
(Darwin, Australia) and the Australian National Univer-
sity (Canberra, Australia). Written informed consent
was obtained from participants in Bahasa Indonesia, and
oral translation was provided as required in an appropri-
ate Papuan language.
Results
One hundred and sixty two smear-positive pulmonary
TB patients were recruited. One hundred and forty one
(87.0%) were offered VCT. Uptake of HIV testing was
high (138/141 = 97.9%); only 3 participants, all female,
declined an HIV test. Eighteen of 138 people (13.0%)
who had an HIV antibody test were HIV positive, con-
firmed with 3 rapid assays. See Table 1.
In total, 21% (14/67) of Papuans were HIV positive
compared to 5.6% (4/71) Non-Papuans (OR 4.4 [95% CI:
1.4-14.2], p = 0.02). Papuan women comprised the high-
est-risk subgroup, although confidence intervals were
wide (Figure 1). HIV+/TB+ participants were less likely
than HIV-/TB+ to be employed (6/18 = 33.3% vs 67/
114 = 58.8%, p = 0.04), and less likely to have achieved
an educational level above primary school (10/18 =
55.6% vs 89/119 = 74.8%, p = 0.05). However, these
associations were no longer significant after controlling
for ethnicity. HIV status was unrelated to age.
Longitudinal trend in TB-HIV co-infection rate
We conducted a study of smear-positive pulmonary TB
patients at the same Timika TB clinic in 2003-2004, in
which HIV status was ascertained in all 112 study parti-
cipants. HIV seroprevalence was 4.5% overall (5/112)
[26]. Comparing this 2003-2004 data with the current
findings, a significant rise in the rate of TB-HIV co-
infection is evident in Timika in the last 4 years (OR =
3.2 [95% CI: 1.2-8.9], p = 0.03, Figure 2).
Clinical characteristics
Clinical characteristics according to HIV status are pre-
sented in Table 1. Study participants with HIV had sig-
nificantly lower exercise tolerance, walking a median 25
m less than those without HIV (p = 0.04). The mean
haemoglobin and white cell counts were significantly
lower in HIV+ patients (mean difference = 1.3 g/dl [95%
CI 0.5-2.2] p = 0.002, and 2.1 × 10
9/L [95% CI 0.5-3.8]
p = 0.01 respectively), with all HIV+ males, and 3/7
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All HIV+ HIV- p value (HIV+ vs HIV-)
Number (%) 138 18 (13.0) 120 (87.0)
Age in years: median (range) 27 (15-65) 31 (16-60) 27 (15-56) 1.0
Papuan: no. (%) 67 (48.6) 14 (77.8) 53 (44.2) 0.01
Female: no. (%) 43 (31.2) 7 (38.9) 36 (30.0) 0.4
Current smoker: no.(%) 42 (30.4) 5 (27.8) 37 (30.8) 0.8
Highest educational attainment: no. (%)
No schooling 10 (7.2) 4 (22.2) 6 (5.0)
Primary school 28 (20.3) 4 (22.2) 24 (20) 0.05*
High school 96 (69.6) 10 (55.6) 86 (71.7)
Academy or university 4 (2.9) 0 (0) 4 (3.3)
Unemployed: no. (%) 59 (44.7) 12 (66.7) 47 (41.2) 0.04*
Owns telephone: no. (%) 77 (55.8) 8 (44.4) 69 (57.7) 0.3
Clinical and laboratory investigations
BMI in kg/m
2: mean (range) 19.3 (12.9-32.5) 19.2 (12.9-26.7) 19.4 (13.3-32.5) 0.8
Percentage of predicted FEV1: mean (range) 63.9 (16.6-108.5) 59.5 (16.5-92.0) 64.6 (23.9-108.5) 0.3
6 minute walk test in m: median (range) 415 (0-612) 390 (0-485) 415 (75-612) 0.04
St George’s Respiratory Questionnaire† total score: median (range) 38.3 (5.2 - 91.9) 41.7 (13.6-67.0) 38.1 (5.2-91.9) 0.4
Haemoglobin in g/dL: mean (range) 12.4 (7.1-16.0) 11.2 (8.5-12.9) 12.6 (7.1-16) 0.002
Anaemia: n (%) 77 (55.8) 14 (77.8) 63 (52.5) 0.053
White cell count × 10
9/L: mean (range) 8.0 (1.6-22.7) 6.8 (2.4-13.2) 9.0 (1.6-22.7) 0.01
Sputum smear ≥2+: no. (%) 61 (45.2) 5 (27.8) 56 (47.9) 0.1
Chest X-ray
Total score: median (IQR) 67 (4-140) 57 (19-121) 68 (6-140) 0.5
Cavitary disease on CXR: no. (%) 74 (55.2) 6 (33.3) 68 (58.6) 0.04
Pleural effusion: no. (%) 23 (17.2) 7 (38.9) 16 (13.8) 0.009
*Differences in education and employment were not significant in multivariate models controlling for ethnicity. †St George’s Respiratory Questionnaire results
were only available in 119 participants (15 HIV+ and 104 HIV-)
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Figure 1 Rates of TB-HIV co-infection among study participants. p values calculated using Fisher’s exact tests
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Page 4 of 9HIV+ females, being anaemic (overall OR 3.2, 95% CI
0.99 - 10.2; Table 1). Pulmonary function was moder-
ately impaired in HIV-/TB+ participants (mean FEV1
64.6%), but moderate-severely impaired in the HIV+/TB
+ participants (mean FEV1 59.5%), however this differ-
ence was not statistically significant (p = 0.3, Table 1).
Weight or BMI and quality of life scores (SGRQ) did
not significantly differ according to HIV status (Table
1). Associations, apart from anaemia, remained the same
when controlling for weight, ethnicity and sex.
Chest x-ray findings differed significantly, with cavi-
tary disease being less common (OR = 0.4, 95% CI 0.1-
1.0), and pleural effusion (i.e. extra-pulmonary TB)
more common (OR = 3.6, 95% CI 1.7-7.6), in the HIV
+/TB+ group compared with HIV-/TB+ group. How-
ever, overall extent of radiological disease (chest x-ray
score) did not differ (Table 1).
Outcome
HIV status did not significantly influence time to spu-
tum smear conversion (hazards ratio [HR] 0.7, 95% CI
0.41 - 1.3, p = 0.2). The HIV+/TB+ group had a similar
overall likelihood of treatment success (HIV+/TB+ cure
or completion: 85.7%; HIV-/TB+ cure or completion:
92.6%, p = 0.2). However, they were more likely to suffer
an unfavourable outcome, which was reported in 16.7%
(3/18) of HIV+/TB+ participants compared with 1.7%
(2/120) of the HIV-/TB+ participants (OR 11.8, 95% CI
1.8-76.4). These comprised in the HIV+/TB+ group: 2
deaths (1 progressive respiratory illness due to TB or
secondary pneumonia, and 1 stroke complicated by
aspiration pneumonia) and 1 hospitalisation (due to
pneumothorax and severe malnutrition, BMI 12.9 kg/
m
2), and in the HIV-/TB+ group, no deaths and 2 hos-
pitalisations (1 vomiting/dehydration and 1 multi-drug
resistant-TB with progressive pulmonary disease and
large pleural effusion). The relationship between HIV
status and default rates could not be determined, since
people who defaulted often did so prior to HIV testing
being offered (of the original 162 study participants, 8
defaulted: of these 3 were HIV negative, none were
known to be positive, and 5 had undetermined status).
HIV Management
CD4 counts were obtained in 6 patients (Table 2).
According to 2006 WHO guidelines, 14 people were eli-
gible for early ART initiation (CD4 < 200 cells/μLo r
unknown), 1 for ART initiation after week 8 (CD4 200-
350), and 3 for deferred ART initiation (CD4 > 350).
However, during their 6-month TB treatment period,
only one person with TB-HIV co-infection was success-
fully commenced and maintained on ART, 1 patient
with known HIV at the time of TB diagnosis was
already taking and remained on ART throughout her
involvement in the study, and 2 additional patients who
had been referred for ART were commenced by the
authorised ART prescriber after their TB treatment was
completed.
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Figure 2 TB-HIV co-infection rates in Timika in 2003-4 compared with 2008-9. p value calculated using Fisher’s exact test.
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TB-HIV co-infection rates
This study has identified that TB-HIV co-infection
rates have increased significantly during 5 years in
Timika, Indonesia. Among the Indigenous Papuan sub-
group, HIV seroprevalence in TB patients rose almost
5-fold to 21%. Although this is still lower than in some
global regions (e.g. 51% for the WHO Africa region
[1]) it is among the highest reported from Asia, and
the rapid rate of change has outstripped local capacity
to adequately respond to the problem. HIV co-infec-
tion rates differ markedly across Asia, ranging from
0.5% in a large study in Guangxi, China [36], to an
estimated 3% overall for Indonesia and 17% in Thai-
land [1]. Published data from neighbouring Papua New
Guinea are scant but similar to rates reported here,
with HIV prevalence in incident TB cases estimated at
19% in 2007 [1].
Differences between HIV positive and negative TB
patients
Reasons for ethnic differences in HIV rates were not
i n v e s t i g a t e di nt h i ss t u d yb u tm a yc o m p r i s eac o m b i n a -
tion of factors including sexual behaviours, knowledge
of sexual health and transmission prevention, and possi-
bly, the difference in male circumcision rates (about 5%
of Papuans and 70% of Non-Papuans are circumcised)
[19]. Injecting drug use is not thought to contribute to
H I Vt r a n s m i s s i o ni nP a p u aP r o v i n c e[ 1 9 ] .T h et r e n d
towards women being at greater risk in Timika is in
keeping with findings elsewhere of higher HIV rates in
young women compared with same-aged men [37]. HIV
+ people were less likely to be educated or employed,
indicating that HIV education is required at the com-
munity level, not just targeting schools or workplaces.
Clinical differences according to HIV status in this
study were not large. A limitation of the study is that the
small numbers mean it may be under-powered to
adequately detect differences between HIV+ and
HIV- groups. No significant differences in symptoms or
perceived health-related quality of life were identified.
Weight (or BMI) was also not different at baseline. This
may indicate that HIV infections overall were not
advanced, also supported by the relatively well-preserved
CD4+ T-cell counts in some individuals (Table 2). These
findings emphasise the importance of routine HIV testing
in TB rather than restricting testing to those with addi-
tional features suspicious for HIV (such as oesophageal
candidiasis), as has been practiced elsewhere [38]. The
HIV+/TB+ group did have significantly lower exercise
tolerance, and a 1.5-fold increased risk of anaemia. The
latter is likely to be multifactorial, with important contri-
butions in the Timika population from impaired nutri-
tion, helminth infection and high rates of multidrug
resistant Plasmodium falciparum and vivax malaria [22].
This illustrates the compounding effect of overlapping
endemic illnesses, potentially contributing to other poor
health outcomes such as the very high maternal and
infant mortality in Timika [39], and known increased
mortality risk in patients with TB-HIV co-infection [5].
Lower rates of cavitary disease and higher likelihood of
pleural effusion were identified among HIV positive people
at TB diagnosis in our study, consistent with previous stu-
dies examining chest x-rays in TB-HIV co-infection
[40,41]. Since cavitation largely determines sputum bacil-
lary grade [42,43], TB-HIV co-infection is also associated
with higher likelihood of smear-negative disease, or low
bacillary density in smear-positive disease, in proportion to
CD4 count [44]. Our data support these findings, although
not reaching statistical significance. Such findings empha-
sise the difficulty of establishing TB diagnoses (based on
sputum smear and radiological appearance) in HIV infec-
tion. Problems in confidently excluding active TB in HIV
contribute to some persisting reluctance to widely roll-out
isoniazid preventive treatment, an important and underuti-
lised strategy for preventing TB in people with HIV/AIDS
[8,45]. Indeed, this strategy is not currently routine in Indo-
nesia. Improving diagnostic sensitivity through inexpensive
measures in laboratories (e.g. sputum concentration prior
to ZN staining, fluorescence microscopy using an inexpen-
sive light-emitting diode light source, or simple culture-
based techniques) [12] and clinics (e.g. educating medical
staff to appreciate radiological pathology characteristic of
TB-HIV co-infection), are not necessarily beyond the
means of lower-income settings.
Barriers to HIV testing and treatment
In this study, HIV status was established in 85% of par-
ticipants. Although the refusal rate was low, missed
Table 2 TB-HIV co-infection management
TB-HIV co-infected study participants
CD4+ T-cell count: no. (%) 6 (33)
CD4+ T-cells/μL: median (range) 318 (18-739)
CD4+ T-cells <200 2
CD4+ T-cells 200-350 1
CD4+ T-cells >350 3
CD4+ T-cells unknown 12
Anti-retroviral therapy: no. (%) 4/18 (22)
Commenced prior to TB diagnosis 1
Commenced during TB treatment 1
Commenced after TB treatment completed 2
ART type
AZT/3TC/nevirapine 3
AZT/3TC/efavirenz 1
Co-trimoxazole: no. (%) 11/18 (61)
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internationally as well as in Timika. For example, the
HIV status was reported in only 35% of Australian TB
cases in 2006 [46], and nearly half of all TB patients in
London were not offered HIV testing in 2003-4 [47].
Barriers to HIV testing in the current study relate pri-
marily to availability of a certified counsellor, availability
of a private room, and the time required to provide
pre-test counselling. Conducting VCT in a confidential
manner is difficult in a crowded TB clinic, reinforcing
previous findings of the requirement for the right struc-
t u r a lc o n d i t i o n st ob ep r e s e n ta tac l i n i ct os u p p o r t
effective VCT [17]. Given the lack of general knowledge
about HIV, reasonably high pre-test probability of a
positive result (especially among Papuans), and the
degree of stigmatisation suffered by HIV positive indivi-
duals [21], the pre-test counselling process in Timika is
justifiably lengthy. On identifying HIV positivity, access
to appropriate care including ART and condoms is lim-
ited; thus the benefit of HIV status knowledge is
reduced. Therefore prevailing attitudes among local
medical staff has been to take a cautious approach, even
if this leads to incomplete ascertainment of HIV status.
Deployment of provider-initiated opt-out HIV testing
has been widely advocated [48] as a strategy to improve
HIV detection rates [9,10,49-51]. However, a stringent
VCT process was introduced in Timika in 2008, stipu-
lating the requirement for written consent, and for only
a doctor or professional with specific certification, to
conduct VCT. A study investigating barriers to HIV
testing among TB patients in another Indonesian pro-
vince identified both patient and health provider factors
as reasons for low VCT uptake [52]. Among patients,
these included low HIV knowledge, the disincentive of
having to access and endure VCT, and fear of knowing
the test results; and among health care providers: low
HIV knowledge, communication issues, concern about
patients feeling offended, stigmatization and additional
work load [52]. Implementing locally-appropriate strate-
gies to improve the proportion of TB patients who are
offered HIV testing is an important priority.
Access to CD4+ T-cell testing was limited due to diffi-
culties in maintaining the analyser and lack of staff famil-
iarity with its operation. Only four (5.6%) of the HIV
positive study participants successfully commenced ART,
2 after TB treatment completion, even though 15 were eli-
gible for ART during TB treatment according to 2006
guidelines. WHO guidelines on the timing of ART initia-
tion in TB have evolved rapidly on the basis of new trials
[14], such that universal ART initiation regardless of CD4
count is now advocated in TB-HIV co-infection [13]. Inte-
gration of TB-HIV is strongly advocated [10,13]. However,
a chief barrier to ART initiation in Timika is the absence
of such integration, with no authorised ART-prescriber
available in the vicinity of the TB clinic. In Indonesia, ART
can be prescribed only by a designated person at nominated
sites (usually hospitals). Even if a patient is successfully
referred to, and attends, a designated ART-prescription site,
reasons for low ART prescription rates cited by medical
staff include concern about potential poor adherence, and
drug toxicities or paradoxical reactions. Use of co-trimoxa-
zole preventive therapy was somewhat better, in 11 of 18
patients, as this was able to be prescribed by any doctor.
However there is still evidently scope for improved utilisa-
tion of this important preventive therapy. Education of
healthcare providers about ways to support adherence and
manage TB-HIV co-infection is therefore greatly needed.
Conclusion
Rising HIV rates have become a serious concern in
southern Papua. Timika has experienced large recent
population fluxes related to the local mining industry
attracting migrants from rural areas and other parts of
Indonesia, and thus presents a classic demographic sce-
nario for burgeoning HIV rates. The association
between HIV and migrant labourers, especially mine
workers and a thriving commercial sex industry, has
been well established elsewhere [53,54].
These data provide an important South-East Asian
perspective on the overlapping TB and HIV epidemics,
and illustrate the added morbidity suffered by HIV+
compared with HIV- individuals with TB. This study
demonstrates that, despite knowledge of TB-HIV man-
agement guidelines and even within the setting of a
well-regarded TB Directly Observed Treatment facil-
ity, management of TB-HIV co-infection poses an
enormous challenge in resource-limited environments.
Multiple interventions are now required at commu-
nity, patient and healthcare provider levels, to address
rising HIV rates and the barriers to testing and treat-
ment. The recent publication of revised WHO guide-
lines on TB-HIV management provides a timely
opportunity to incorporate these into national guide-
lines, and support their implementation in community
settings.
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